Dark

PYPD
Polypid Ltd
stock NASDAQ

At Close

9/28/2023 3:44:30 PM EDT

4.65USD-2.105%(-0.10)6,560

4.65Bid 4.70Ask 0.05Spread IEX

Pre-market

9/27/2023 8:54:30 AM EDT

4.61USD-2.947%(-0.14)0

After-hours

9/20/2023 4:05:30 PM EDT

0.3371USD+34.840%(+0.0871)0

Overview Option Chain HistoricalNews

Jan 26, 2022

07:30AM EST PolyPid to Report Fourth Quarter and Full Year 2021 Financial GlobeNewswire Inc

Jan 4, 2022

07:30AM EST PolyPid Appoints UCSF Brain Tumor Center Director Mitchel S. GlobeNewswire Inc

Jan 3, 2022

08:17AM EST PolyPid Ltd. (PYPD), an Israeli biopharmaceutical firm, said on Monday that its Chief Executive Officer or CEO Amir Weisberg, will retire from the service with effect from July 1. RTTNews

07:37AM EST PolyPid Appoints Dikla Czaczkes Akselbrad As CEO, Effective July 1 RTTNews

07:31AM EST PolyPid Appoints Dikla Czaczkes Akselbrad CEO Benzinga

07:30AM EST PolyPid Announces Planned CEO Transition GlobeNewswire Inc

Nov 18, 2021

07:05AM EST PolyPid Announces 500th Patient Enrolled In SHIELD I Phase 3 Clinical Trial Of D-PLEX In Abdominal Surgery Benzinga

07:00AM EST PolyPid Announces 500th Patient Enrolled in SHIELD I Phase 3 GlobeNewswire Inc

Nov 16, 2021

07:00AM EST PolyPid Ltd. (Nasdaq: PYPD) (PolyPid or the Company), a phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLEX technology, today announced the appointment of Frederick Lang, M.D., to its Oncology Advisory Board. GlobeNewswire Inc

Nov 10, 2021

07:32AM EST PolyPid Q3 EPS $(0.53) Beats $(0.62) Estimate Benzinga

07:00AM EST Recruitment Progressing as Planned with Approximately 480 Patients Enrolled in Phase 3 SHIELD I Trial of D-PLEX100in Abdominal Surgery GlobeNewswire Inc

04:09AM EST Earnings Scheduled For November 10, 2021 Benzinga

Nov 1, 2021

07:00AM EDT PolyPid to Report Third Quarter 2021 Financial Results and GlobeNewswire Inc

Oct 18, 2021

10:21AM EDT Overview Of Value Stocks In The Healthcare Sector Benzinga

Sep 20, 2021

10:44AM EDT 5 Value Stocks In The Healthcare Sector Benzinga

07:00AM EDT PolyPid Ltd. (Nasdaq: PYPD), a phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLEX technology, today announced its participation in the Cantor Fitzgerald Virtual Global Healthcare Conference on September 29 at 02:00 pm EDT. GlobeNewswire Inc

Sep 14, 2021

10:16AM EDT Benzinga's Top Ratings Upgrades, Downgrades For September 14, 2021 Benzinga

06:23AM EDT JMP Securities Initiates Coverage On PolyPid with Market Outperform Rating, Announces Price Target of $14 Benzinga

Sep 13, 2021

10:27AM EDT A Look Into Healthcare Sector Value Stocks Benzinga

07:49AM EDT PolyPid Announces Positive Preclinical Data Of Its Intra-tumoral OncoPLEX In Brain Cancer RTTNews

07:42AM EDT PolyPid Announces Preclinical Data In Glioblastoma Multiform Animal Models Of OncoPLEX Program; Says Results Demonstrated 'Single Local Treatment of OncoPLEX Significantly Inhibited Tumor Growth and Prolonged Survival' Benzinga

07:30AM EDT -- Positive Results in Two Animal Models of Glioblastoma Multiform (GBM) demonstrated that Single Local Treatment of OncoPLEX Significantly Inhibited Tumor Growth and Prolonged Survival -- Company Expects a Pre-IND Meeting with the U.S. FDA by Year End and Potential Initiation of Phase 1/2 Clinical Trial of OncoPLEX in Brain Tumors in 2022 GlobeNewswire Inc

Aug 17, 2021

08:00AM EDT PolyPid to Present at First World Association Against Infection in GlobeNewswire Inc

Aug 11, 2021

09:06AM EDT Earnings Scheduled For August 11, 2021 Benzinga

07:29AM EDT PolyPid Q2 EPS $(0.56) Misses $(0.52) Estimate Benzinga

07:00AM EDT Recruitment Progressing as Planned with Over300 Patients Enrolled into Phase 3 SHIELD I Trial of D-PLEX100in Abdominal Surgery GlobeNewswire Inc

04:27AM EDT Earnings Scheduled For August 11, 2021 Benzinga

Aug 9, 2021

08:00AM EDT PolyPid Ltd.(Nasdaq: PYPD), a late-stage biopharma company aiming to improve surgical outcomes through locally administered, controlled, extended-release therapeutics, today announced that Executive Vice President and Chief Financial Officer Dikla Czaczkes Akselbrad will present a corporate overview at the Investor Summit Virtual Conference being held August 17 18, 2021. GlobeNewswire Inc

Jul 30, 2021

10:02AM EDT Benzinga's Top Ratings Upgrades, Downgrades For July 30, 2021 Benzinga

07:49AM EDT Cantor Fitzgerald Initiates Coverage On PolyPid with Overweight Rating, Announces Price Target of $24 Benzinga

Jul 28, 2021

07:33AM EDT The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal Benzinga

07:00AM EDT PolyPid to Report Second Quarter 2021 Financial Results and GlobeNewswire Inc

Jul 20, 2021

08:20AM EDT The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street Benzinga

Jul 16, 2021

07:37AM EDT The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study Benzinga

Jul 15, 2021

08:08AM EDT The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs Benzinga

Jul 14, 2021

07:48AM EDT The Daily Biotech Pulse: ScPharma's Positive Data, Lilly Goes Shopping, LeMaitre Pre-Announces Q2 Revenues Benzinga

Jul 12, 2021

08:00AM EDT PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharma company focusing on developing targeted, locally administered and prolonged-release therapeutics to improve surgical outcomes, today announced that it has appointed leading colorectal surgeon Anthony J. Senagore, M.D., as its Senior Medical Director. GlobeNewswire Inc

Jul 2, 2021

04:28PM EDT PolyPid Files For Stock Shelf Offering Of Up To $200M Benzinga

Jun 23, 2021

06:30AM EDT PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharma company aiming to improve surgical outcomes through locally administered, controlled, extended-release therapeutics, announced that Dikla Czaczkes Akselbrad, Executive Vice President and Chief Financial Officer will present today at The Raymond James Human Health Innovation Conference at 9:20 am EDT. GlobeNewswire Inc

Jun 2, 2021

09:10AM EDT PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharma company aiming to improve surgical outcomes through locally administered, controlled, extended-release therapeutics, today announced that members of its executive management team will present at three upcoming healthcare investor conferences. GlobeNewswire Inc

May 19, 2021

12:53PM EDT PolyPid's Single Pivotal Study Sufficient To Support Potential Approval Of D-PLEX100 For Infections After Colorectal Surgery Benzinga

08:03AM EDT PolyPid Reports Positive FDA Type B Meeting Feedback For D-PLEX100 Development Program Benzinga

08:00AM EDT FDA Agreed that a Single Pivotal Phase 3 Study is Sufficient for Potential Approval of D-PLEX100for the Prevention of Surgical Site Infections in Colorectal Surgery. GlobeNewswire Inc

May 13, 2021

08:10AM EDT The Daily Biotech Pulse: Merck Reports Positive Keytruda Data In Breast Cancer, Curis, Evoke Slump On Earnings, Qiagen's Rapid COVID-19 Antibody Test OK'ed For Emergency Use Benzinga

May 12, 2021

08:57AM EDT The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron Benzinga

07:13AM EDT PolyPid Q1 EPS $(0.47) Beats $(0.50) Estimate Benzinga

07:00AM EDT Recruitment Progressing as Planned with Nearly 200 Patients Enrolled into Phase 3 SHIELD I Trial of D-PLEX100 in Abdominal Surgery GlobeNewswire Inc

04:22AM EDT Earnings Scheduled For May 12, 2021 Benzinga

Apr 29, 2021

07:00AM EDT PolyPid to Report First Quarter 2021 Financial Results and GlobeNewswire Inc

Mar 31, 2021

07:41AM EDT The Daily Biotech Pulse: Pfizer Vaccine 100% Effective In Adolescents, Equillium Readout, Amgen Goes Shopping, Achilles IPO Benzinga

Feb 23, 2021

07:30AM EST PolyPid to Participate in Upcoming Investor Conferences GlobeNewswire Inc

Feb 16, 2021

07:35AM EST PolyPid Highlights 100th Patient Enrolled In SHIELD I Phase 3 Clinical Trial Of D-PLEX For The Prevention Of Post-Abdominal Surgery Incisional Infections Benzinga

07:31AM EST PolyPid Announces 100th Patient Enrolled in SHIELD I Phase 3 GlobeNewswire Inc

Feb 11, 2021

11:21AM EST Stocks That Hit 52-Week Highs On Thursday Benzinga

Feb 10, 2021

07:34AM EST The Daily Biotech Pulse: Lilly COVID-19 Antibody Cocktail Approved for Emergency Use, Gamida, Genfit Jump On Data, 2 IPOs Benzinga

07:07AM EST PolyPid Q4 EPS $(0.41) Beats $(0.51) Estimate Benzinga

07:00AM EST -- 100Patients Enrolled into Phase 3 SHIELD I and SHIELD II Trialsof D-PLEX100 in Abdominal Surgery -- Recently Initiated Phase 3 SHIELD II Trial -- Granted Breakthrough Therapy Designation from FDA for D-PLEX100 for Prevention of SSIs in Patients Undergoing Elective Colorectal Surgery -- Conference Call Scheduled for Today at 8:30AMET GlobeNewswire Inc

03:43AM EST Earnings Scheduled For February 10, 2021 Benzinga

Feb 6, 2021

12:42PM EST The Week Ahead In Biotech (Feb. 7-13): Regeneron FDA Decision, Earnings, IPOs and Conference Presentations In The Spotlight Benzinga

Jan 27, 2021

07:30AM EST PolyPid to Report Fourth Quarter and Full Year 2020 Financial GlobeNewswire Inc

Dec 22, 2020

07:09AM EST PolyPid Reports Preclinical Data From OncoPLEX Intra-Tumoral Cancer Therapy Program: Showed Overall Survival, Significantly Less Tumor Recurrence Benzinga

07:04AM EST PolyPid Announces Positive Preclinical Data From OncoPLEX Intra-Tumoral Cancer Therapy Program RTTNews

07:00AM EST Single Local Treatment of OncoPLEX Showed Improved Overall Survival and Significantly Less Tumor Recurrence, and Reduced Systemic Toxicity Compared to Multiple Injections with Standard Systemic Chemotherapy in a Syngeneic Mouse Model for Solid Tumors of Colon Carcinoma GlobeNewswire Inc

03:57AM EST The lockup period of PolyPid Ltd. (PYPD) ends tomorrow, i.e., December 23. RTTNews

Dec 16, 2020

07:11AM EST PolyPid Initiates SHIELD II: Second Phase 3 Clinical Trial Of D-PLEX For Prevention Of Post-Abdominal Surgery Incisional Infections Benzinga

07:01AM EST Enrollment in SHIELD I, the First Phase 3 Clinical Trial Continues to Progress, with Top-line Data Anticipated in Second Half of 2021 GlobeNewswire Inc

Dec 3, 2020

08:00AM EST PolyPid to Host Key Opinion Leader Call Discussing GlobeNewswire Inc

Nov 24, 2020

08:18AM EST PolyPid Reports Was Granted Breakthrough Therapy Designation From FDA For D-PLEX For Prevention Of Surgical Site Infections In Colorectal Surgery Benzinga

08:17AM EST PolyPid Granted Breakthrough Therapy Designation from FDA for GlobeNewswire Inc

Nov 20, 2020

08:06AM EST The Daily Biotech Pulse: Amarin Surges On Vascepa Data, Mesoblast Rallies On Novartis Deal, Decision Day For Eiger Benzinga

Nov 19, 2020

08:17AM EST The Daily Biotech Pulse: Aquestive's Positive FDA Meeting, Prevail Awarded Patent, Neuro-Oncology Conference Gets Underway Benzinga

Nov 12, 2020

07:44AM EST The Daily Biotech Pulse: AstraZeneca's Cancer Drug Flunks COVID-19 Studies, Five Prime On a Roll, Morphosys, Xencor, Incyte Strike Cancer Deal Benzinga

Nov 11, 2020

07:38AM EST The Daily Biotech Pulse: Five Prime Skyrockets, Multiple Conference Presentations On Tap Benzinga

06:34AM EST PolyPid Q3 EPS $(0.35) Beats $(0.39) Estimate Benzinga

06:30AM EST Over 50% of planned 60 centers for ongoing Phase 3 SHIELD I trial of D-PLEX100in abdominal surgeryhave received IRB approval GlobeNewswire Inc

04:09AM EST Earnings Scheduled For November 11, 2020 Benzinga

Nov 4, 2020

08:45AM EST PolyPid to Participate in Three Upcoming Investor Conferences GlobeNewswire Inc

Oct 28, 2020

07:00AM EDT PolyPid to Report Third Quarter 2020 Financial Results and GlobeNewswire Inc

Aug 19, 2020

07:21AM EDT PolyPid Q2 EPS $(6.37) Misses $(0.37) Estimate Benzinga

07:00AM EDT Initiated Phase 3 SHIELD I Trial for D-PLEX100 in Abdominal Surgery and Received Fast Track Designation for D-PLEX100from FDA GlobeNewswire Inc

04:02AM EDT Earnings Scheduled For August 19, 2020 Benzinga

Aug 10, 2020

10:25AM EDT Benzinga's Top Upgrades, Downgrades For August 10, 2020 Benzinga

07:14AM EDT Alliance Global Partners Initiates Coverage On PolyPid with Buy Rating, Announces Price Target of $27 Benzinga

Aug 5, 2020

04:02PM EDT PolyPid to Report Second Quarter 2020 Financial Results and GlobeNewswire Inc

Aug 3, 2020

07:20AM EDT PolyPid Gets FDA Fast Track Designation For D-PLEX For Prevention Of Surgical Site Infections In Abdominal Surgery RTTNews

07:05AM EDT PolyPid Granted Fast Track Designation from FDA for D-PLEX for Prevention of Surgical Site Infections in Abdominal Surgery Benzinga

07:00AM EDT PolyPid Granted Fast Track Designation from FDA for GlobeNewswire Inc

Jul 27, 2020

07:00AM EDT PolyPid to Present Phase 2 Results of GlobeNewswire Inc

Jul 21, 2020

09:37AM EDT Benzinga's Top Upgrades, Downgrades For July 21, 2020 Benzinga

08:19AM EDT Raymond James Initiates Coverage On PolyPid with Outperform Rating, Announces Price Target of $23 Benzinga

07:27AM EDT BMO Capital Initiates Coverage On PolyPid with Outperform Rating, Announces Price Target of $30 Benzinga

06:06AM EDT Barclays Initiates Coverage On PolyPid with Overweight Rating, Announces Price Target of $22 Benzinga

.dark-mode .t3RXZ7{ color: white; background-color: #333333; border: 2px solid white; }.light-mode .t3RXZ7{ color: #333333; background-color: white; border: 2px solid #333333; }PYPDPolypid Ltdstock NASDAQ

PYPD
Polypid Ltd
stock NASDAQ